#BEGIN_DRUGCARD DB00671

# AHFS_Codes:
08:12.06.12

# ATC_Codes:
J01DD08

# Absorption:
About 40%-50% absorbed orally whether administered with or without food, however, time to maximal absorption is increased approximately 0.8 hours when administered with food.

# Biotransformation:
Hepatic. Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours.

# Brand_Mixtures:
Not Available

# Brand_Names:
CFIX
Cefixoral
Cefspan
Cephoral
Oroken
Suprax
Unixime

# CAS_Registry_Number:
79350-37-1

# ChEBI_ID:
472657

# Chemical_Formula:
C16H15N5O7S2

# Chemical_IUPAC_Name:
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2195992

# Description:
Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.

# Dosage_Forms:
Powder, for suspension	Oral
Tablet	Oral

# Drug_Category:
Anti-Bacterial Agents
Cephalosporins

# Drug_Interactions:
Probenecid	Probenecid may increase the serum level of cefixime.

# Drug_Reference:
17509176	McMillan A, Young H: The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime. Int J STD AIDS. 2007 Apr;18(4):253-4.
8537138	Adam D, Hostalek U, Troster K: 5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy. Cefixime Study Group. Infection. 1995;23 Suppl 2:S83-6.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.4

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
55.11 mg/L

# Food_Interactions:
Preferably on an empty stomach, rate of absorption is decreased but extenet of absorption remains the same: not really problematic.

# GenBank_ID:
Not Available

# Generic_Name:
Cefixime

# HET_ID:
Not Available

# Half_Life:
3-4 hours (may range up to 9 hours). In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours.

# InChI_Identifier:
InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1

# InChI_Key:
InChIKey=OKBVVJOGVLARMR-QSWIMTSFSA-N

# Indication:
For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by <i>Escherichia coli</i> and <i>Proteus mirabilis</i>, (2) otitis media caused by <i>Haemophilus influenzae</i> (beta-lactamase positive and negative strains), <i>Moraxella catarrhalis</i> (most of which are beta-lactamase positive), and <i>S. pyogenes</i>, (3) pharyngitis and tonsillitis caused by <i>S. pyogenes</i>, (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by <i>Neisseria gonorrhoeae</i> (penicillinase- and non-penicillinase-producing strains).

# KEGG_Compound_ID:
C06881

# KEGG_Drug_ID:
D00258

# LIMS_Drug_ID:
671

# Mechanism_Of_Action:
Like all beta-lactam antibiotics, cefixime binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefixime interferes with an autolysin inhibitor.

# Melting_Point:
218-225 Â°C

# Molecular_Weight_Avg:
453.45

# Molecular_Weight_Mono:
453.041289239

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/sup1416.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164768821

# Pharmacology:
Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.

# Predicted_LogP_Hydrophobicity:
0.25

# Predicted_LogS:
-3.6

# Predicted_Water_Solubility:
1.04e-01 g/l

# Primary_Accession_No:
DB00671

# Protein_Binding:
65% (concentration independent)

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/cefixime.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00583

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Cefixim
Cefixima [Spanish]
Cefixime Anhydrous
Cefiximum [Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.

# Update_Date:
2013-02-08 16:19:32 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cefixime

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Bacterial cell inner membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
16940068	Takahata S, Senju N, Osaki Y, Yoshida T, Ida T: Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. Epub 2006 Aug 28.
19528266	Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas RA: Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51. Epub 2009 Jun 15.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L42023

# Drug_Target_1_GenBank_ID_Protein:
1572976

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
mrdA

# Drug_Target_1_Gene_Sequence:
>1956 bp
TTATCTTCCATTTATTTGTTCGCTCTCTTGTGACAAATCTTTTTTTTGCTGAATAGGTAC
ATTATATTTTTCAACTTGTGGTAAACGCTGATTTAAATAGTAATCCATCACTTTACGTGC
TAAGGGTGCGGCATTACTTGAACCACCACCTGCATTTTCTAAAATCACTGTTACAACTAA
TTTAGGATTATCATAAGGGGCGTAAGCGGTAAACCAAGCGTGATCATGCAATTCTTTTTT
TAAGCCTGCCGTATTATATTTTTCATTTTCCTTTAAACTAAACACTTGTGCAGTGCCAGA
TTTCCCTGCAACACGATAATTTGCATCTGCAAAGGCTTTTCGCCCAGTTCCATTTGCAGC
ATTAACAACATTGTACATACCGCGTTTCGCTGCCTCCCAAGCTGCCACTTTAGGTGTATT
AATATCAGGATAAAGTAACGGATCTTCATAAGGCTCTAATACTGCACCTTCAATTGCTTT
CATCAAATGCGGTGTATTTACTTTGCCATTATTGACCAATATTGTCGTCGCTTTTGCTAC
TTGTAGTGGTGTTGCCGTCCAATAACCTTGACCAATCCCAACCGAAATCGTATCGCCTTG
CACCCAAGGGCGTTTATAACGTTTTTGTTTCCATTCTCGAGTTGGTATATTGGCAGCCGT
TTCTTCTTGAATTTCAATCCCCGTTGGCATACCAAAACCAAAATCCTTCATCCAATTAGA
AAGGCGATCAATACCCATATTATAAGCCACTTGATAAAAATAAGTATCAGAGGATTCAGT
AATCGCTTTATTCAAATCCGTATCCCCGTGGCCTGTTTTTTTCCAATCACGAAAACGTTT
TGTGGAATTAGGTAATACCCAATATCCCGGATCAAAAATCGTTGTGTTTGGTGTAATCAC
ATTTTCAGTTTGTGCGGCTACTGCAATAAAAGGTTTGACTGTCGAAGCGGGCGGATACGC
ACCTTGTGTCGCACGACTATAAAGTGGACGAGCAAGATCATTTAATAAACGTTTATAATC
TTCGGAGGAAATACCATCAACAAATAAATTATTATCATAACTTGGTGTAGATACCATCGC
TAATACACTACTATCTTTCGGATCAAGCACAACTACAGCACCTTTTAGTCCCGATAAAAG
TTCAGTAATATAACGCTGTAATGCCAAATCAATGGTTAAATGAATACTTTTTCCCGCCAC
AGCAGGTCGGCTACGCAAAGTGCGGATTACTTTGCCGCGATTATTAATTTCTACTTCTTC
AAAACCCGTGGTACCTTGCAGTATATCCTCGTAATAACGTTCAATACCCAATTTTCCAAT
ATCGTTCGTTCCCGCATAATTCGCGAATTTATCCTCTCGTTTCAAACGTTCTACATCTTT
ATCATTCATTTTACCTACATAGCCCAAAATATGCGCCATTGTTTCGCCATATAAATAATG
GCGTTTGAAATAAGGACGTACCTCTAAGCTCGGGTATTGGTAGCCATTTACCGCAAAGCG
TGAAATTTGTTCTTCTGTTAAATTCGGCTTTAATAAAATCGGTGTATAACGCGTTCCGCG
GCGACGTTCCTTTTTAAAATTTTCAATATCGTTATCCGTCAATCCCACAATATAGCGTAA
TTCATCTAAAGTGCGGTCTAAATTTTCAGTTTTTTCTGGCACAATGTATAAACCAAAAAA
AGTAAGATTTTCGGCTAATAATTTGCCGTAACGATCATAGATTAAGCCACGTGTTGGCGG
TAAAGGTAATAATTTAATTCGGTTACCATTAGAACGCGTTTGGTAAGTATCGAAATTAAC
AATCTGTAGCTGATAAATATTGGTGAATAACACGCCTGTTAAGAGCAGAATCCCCAAAAA
AGCCACTAACGTTCGGCGTGCAAAAAGGTTACGCTCCGCTTTTTTATCGCGGAACGGTTC
GTGCGTTGGTGTATTGAAGAATTTTTTTAAATTCAT

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
115

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
73814

# Drug_Target_1_Name:
Penicillin-binding protein 2

# Drug_Target_1_Number_of_Residues:
651

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 2
MNLKKFFNTPTHEPFRDKKAERNLFARRTLVAFLGILLLTGVLFTNIYQLQIVNFDTYQT
RSNGNRIKLLPLPPTRGLIYDRYGKLLAENLTFFGLYIVPEKTENLDRTLDELRYIVGLT
DNDIENFKKERRRGTRYTPILLKPNLTEEQISRFAVNGYQYPSLEVRPYFKRHYLYGETM
AHILGYVGKMNDKDVERLKREDKFANYAGTNDIGKLGIERYYEDILQGTTGFEEVEINNR
GKVIRTLRSRPAVAGKSIHLTIDLALQRYITELLSGLKGAVVVLDPKDSSVLAMVSTPSY
DNNLFVDGISSEDYKRLLNDLARPLYSRATQGAYPPASTVKPFIAVAAQTENVITPNTTI
FDPGYWVLPNSTKRFRDWKKTGHGDTDLNKAITESSDTYFYQVAYNMGIDRLSNWMKDFG
FGMPTGIEIQEETAANIPTREWKQKRYKRPWVQGDTISVGIGQGYWTATPLQVAKATTIL
VNNGKVNTPHLMKAIEGAVLEPYEDPLLYPDINTPKVAAWEAAKRGMYNVVNAANGTGRK
AFADANYRVAGKSGTAQVFSLKENEKYNTAGLKKELHDHAWFTAYAPYDNPKLVVTVILE
NAGGGSSNAAPLARKVMDYYLNQRLPQVEKYNVPIQQKKDLSQESEQINGR

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. Its synthesize cross- linked peptidoglycan from the lipid intermediates

# Drug_Target_1_SwissProt_ID:
P44469

# Drug_Target_1_SwissProt_Name:
PBP2_HAEIN

# Drug_Target_1_Synonyms:
PBP-2

# Drug_Target_1_Theoretical_pI:
9.66

# Drug_Target_1_Transmembrane_Regions:
30-52

#END_DRUGCARD DB00671
